{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/seborrhoeic-dermatitis/management/seborrhoeic-dermatitis-face-body/","result":{"pageContext":{"chapter":{"id":"ad81b0ed-2e0c-5a1d-a7a0-e823d40d7ca4","slug":"seborrhoeic-dermatitis-face-body","fullItemName":"Scenario: Seborrhoeic dermatitis - face and body","depth":2,"htmlHeader":"<!-- begin field 3c5a8681-9ef1-464c-abe3-102e82e7e99e --><h2>Scenario: Seborrhoeic dermatitis - face and body</h2><!-- end field 3c5a8681-9ef1-464c-abe3-102e82e7e99e -->","summary":"Covers what advice to give, how to manage seborrhoeic dermatitis of the face and body, and when to follow up or refer.","htmlStringContent":"<!-- begin item 311b75ca-670c-4a51-a3d8-39adf99c168b --><!-- begin field 14192e99-ba67-455e-adac-acbc0158da22 --><p>From age 12 months onwards.</p><!-- end field 14192e99-ba67-455e-adac-acbc0158da22 --><!-- end item 311b75ca-670c-4a51-a3d8-39adf99c168b -->","topic":{"id":"b328d01a-a44a-57e1-8920-22321b4c6c8b","topicId":"67c69cb5-e030-443e-802f-758ce0fe90f8","topicName":"Seborrhoeic dermatitis","slug":"seborrhoeic-dermatitis","lastRevised":"Last revised in February 2019","chapters":[{"id":"2c32aabf-f751-57c2-9fb1-bfd7e4c7e58d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"96bfb0b4-09f0-5525-aaf3-ca2354a87cb4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9bf8c16e-f128-5c6a-b6e8-d4223dcf2346","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"debcdac6-7ef3-5820-90b8-353614354fc7","slug":"changes","fullItemName":"Changes"},{"id":"32308918-ad23-5b7d-a1c5-7c7a4edf3e35","slug":"update","fullItemName":"Update"}]},{"id":"efc69a37-1a91-539d-b4ce-b1cfc1d48baf","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"09ce3910-2aa3-537d-97db-f473bf3f3c99","slug":"goals","fullItemName":"Goals"},{"id":"37776aed-67d4-5001-8e82-0fec56ecaa71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2638b372-65f4-549c-9c2d-fff4cf1c933d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"df03f868-28e0-52a9-9f30-aecfccaa745c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bf290438-2d1b-5233-a43a-e3fe0cbccaab","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d66aeca6-f9ff-5104-94d3-d115d20ad7d1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5f9559ed-2d1c-52f3-ae50-cb983d1b7c7c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025302eb-268d-585c-b9a4-d83b4dbb0e5b","slug":"definition","fullItemName":"Definition"},{"id":"43d0a434-92b2-5c53-b4bd-f8ab32a8c0a3","slug":"causes","fullItemName":"Causes"},{"id":"0f04315e-ba03-5be7-a5dc-c724c1e3fe90","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad49e37a-e725-5ad1-9e7b-f84a79627169","slug":"complications","fullItemName":"Complications"},{"id":"50cfb7dd-1ad7-5d22-9c7e-8472fb0af48c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"26dec6e1-8806-50b7-869d-1e010fa15e89","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f674962-dade-5ce5-9b92-60820da005f7","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"f384b060-7f9e-593e-8a77-6bbf957fd0c4","slug":"assessment","fullItemName":"Assessment"},{"id":"2b98bc5c-ae88-522e-89c4-79e05d301c3f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"521d1a4a-9184-5872-ab66-2a3fed074cc8","fullItemName":"Management","slug":"management","subChapters":[{"id":"ca5edad5-d74c-565f-b254-2c59bed62420","slug":"seborrhoeic-dermatitis-infants","fullItemName":"Scenario: Seborrhoeic dermatitis - infants"},{"id":"4172af9c-8f8b-5bcc-a160-ca83f520099c","slug":"seborrhoeic-dermatitis-scalp-beard","fullItemName":"Scenario: Seborrhoeic dermatitis - scalp and beard"},{"id":"ad81b0ed-2e0c-5a1d-a7a0-e823d40d7ca4","slug":"seborrhoeic-dermatitis-face-body","fullItemName":"Scenario: Seborrhoeic dermatitis - face and body"},{"id":"715da1f8-f458-5eec-96e8-85e22060d505","slug":"seborrhoeic-dermatitis-severe-or-widespread","fullItemName":"Scenario: Seborrhoeic dermatitis - severe or widespread"}]},{"id":"bac53cb4-0b97-5d4b-8ce4-07a9584a5e4f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"970b1e50-a3fc-503d-bbe8-29ecfa575d20","slug":"products-available-otc","fullItemName":"Products available OTC"},{"id":"9b1c8434-e7ce-5cd0-8c49-9e1076fbcecb","slug":"topical-imidazoles","fullItemName":"Topical imidazoles"},{"id":"d35c5c70-d96b-5a9a-a708-2e051cf3cece","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"}]},{"id":"b5cb8438-116a-5790-9b0f-2a480c577056","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"03823e51-3fec-53db-8dde-3fbe6e94526c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"364fda13-808d-599d-84cd-2b31ed7d0d94","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fd9a5e23-6ee9-503f-bbc4-7239d8555e0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1120e62a-fd06-536e-8caf-945332e36549","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"214850c4-e7af-5924-9a63-09325facd062","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bfa9b404-d181-55eb-a3b2-8da0ee4edb43","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5171db55-6873-590e-b670-2d66a4b1b1eb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"521d1a4a-9184-5872-ab66-2a3fed074cc8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"315fa99c-420f-5baa-924a-da85ecc27443","slug":"management-of-face-body","fullItemName":"Management of face and body","depth":3,"htmlHeader":"<!-- begin field 7052f611-4074-44f8-8dee-1f6a305ec5bb --><h3>How should I treat seborrhoeic dermatitis of the face and body?</h3><!-- end field 7052f611-4074-44f8-8dee-1f6a305ec5bb -->","summary":null,"htmlStringContent":"<!-- begin item 40be8b32-f228-4572-8655-891a390f34e1 --><!-- begin field 261422cf-eacb-49a8-be5a-072637965399 --><ul><li><strong>Advise the person:</strong><ul><li>That seborrhoeic dermatitis in adults is a chronic condition and long‐term maintenance treatment may be needed — some people may only require intermittent treatment for flares.</li><li>To avoid use of soap and shaving cream on the face if they cause irritation — non-greasy emollients or emollient soap substitutes should be used.</li><li>Stress may exacerbate seborrhoeic dermatitis and lead to flares.</li></ul></li><li><strong>Provide patient information — available from:</strong><ul><li>The British Association of Dermatologists — <a data-hyperlink-id=\"43a6dc52-bb97-4c06-9072-a9ff00beda62\" href=\"http://www.bad.org.uk/for-the-public/patient-information-leaflets/seborrhoeic-dermatitis\" target=\"_blank\">Seborrhoeic dermatitis</a>.</li><li>The National Eczema Association — <a data-hyperlink-id=\"cafd04fb-a0b0-41c1-a698-a9ff00bedaff\" href=\"https://nationaleczema.org/eczema/types-of-eczema/seborrheic-dermatitis/\" target=\"_blank\">Seborrhoeic dermatitis</a>.</li></ul></li><li><strong>For adults, treat seborrhoeic dermatitis of the face and body with:</strong><ul><li>Ketoconazole 2% cream (once or twice a day) or another imidazole cream (clotrimazole or miconazole) for at least 4 weeks. An antifungal shampoo such as ketoconazole 2% can be used as body wash.<ul><li>Advise the person that once they feel symptoms are under control, ketoconazole cream can be used less frequently (for example twice a week, once a week, once every other week) to prevent recurrence.</li></ul></li><li>Consider adding in a mildly potent topical corticosteroid such as hydrocortisone 0.5% or hydrocortisone 1% for flares to help settle inflammation.<ul><li>Mild topical corticosteroids should only be used short-term (one to two weeks — consider the potential for adverse effects (for example thinning of the skin).</li><li>For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a>.</li></ul></li><li>If the eyelids are involved, consider daily hygiene measures using cotton buds moistened with baby shampoo.<ul><li>For more information on eyelid hygiene techniques, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/blepharitis/\">Blepharitis</a>.</li></ul></li></ul></li><li><strong>For children and adolescents, treat seborrhoeic dermatitis of the face and body with:</strong><ul><li>An imidazole cream (clotrimazole [2–3 times per day] or miconazole [twice daily]) for up to 4 weeks. Ketoconazole cream is not licenced for use in children.</li><li>Consider adding in a mildly potent topical corticosteroid such as hydrocortisone 0.5% or hydrocortisone 1% for flares to help settle inflammation.<ul><li>Mild topical corticosteroids should only be used short-term (one week) — consider potential for adverse effects (for example thinning of the skin).</li><li>For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a>.</li></ul></li><li>In adolescents, an antifungal shampoo such as ketoconazole 2% (not licenced in children under the age of 12 years) may be used as a body wash.<ul><li>Shampoo should be left on for 5 minutes before rinsing off.</li></ul></li><li>If the eyelids are involved advise daily hygiene measures using cotton buds moistened with baby shampoo.<ul><li>For more information on eyelid hygiene techniques, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/blepharitis/\">Blepharitis</a>.</li></ul></li></ul></li><li><strong>Routine follow up is not usually required, however, the person should be advised to attend for review if:</strong><ul><li>Response to treatment is poor.</li><li>Symptoms worsen despite treatment.</li><li>Signs of infection (for example crusting, oozing, bleeding) develop.</li></ul></li><li><strong>Consider referral to a dermatologist/paediatrician if there is:</strong><ul><li>Diagnostic uncertainty.</li><li>Failure to respond to routine treatment — consider drug resistance and <a class=\"topic-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/diagnosis/differential-diagnosis/\">other causes</a>.</li><li>Severe or widespread seborrhoeic dermatitis — for more information, see <a class=\"topic-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/management/seborrhoeic-dermatitis-severe-or-widespread/\">Scenario: Seborrhoeic dermatitis - severe or widespread</a>.</li><li>Eyelid involvement (where simple eyelid hygiene measures have been unsuccessful).</li></ul></li></ul><!-- end field 261422cf-eacb-49a8-be5a-072637965399 --><!-- end item 40be8b32-f228-4572-8655-891a390f34e1 -->","subChapters":[{"id":"59e89aaf-2078-597e-956c-1f638883dcd2","slug":"basis-for-recommendation-81d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 33d699bf-eb00-460d-8683-fb737f8adacf --><h4>Basis for recommendation</h4><!-- end field 33d699bf-eb00-460d-8683-fb737f8adacf -->","summary":null,"htmlStringContent":"<!-- begin item 81d2795a-4a8d-4f87-8878-04af4264a985 --><!-- begin field d41dcfb2-0e84-4e38-80b3-f6252bd43d57 --><p>The recommendations on the management of seborrhoeic dermatitis affecting the face and body are based on clinical guidance from the World Health Organisation <em>Evidence and recommendations on seborrhoeic dermatitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">WHO, 2014</a>], <em>Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Hald, 2015</a>] and the Primary Care Dermatological Society <em>Seborrhoeic eczema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">PCDS, 2016</a>], and expert opinion from the British Association of Dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>], Rook’s textbook of dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Dessinioti, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Borda, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Clark, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BMJ Best Practice, 2018</a>].</p><h5>General advice </h5><ul><li>Treatment is suppressive rather than curative, and as such, seborrhoeic dermatitis often comes back after treatment has stopped. Treatment may have to be used for months or even years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>].</li><li>Cosmetic products containing alcohol solutions usually aggravate inflamed skin and should be avoided [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Berth-Jones, 2010</a>]. Soap and shaving cream may be irritating when applied to affected skin. Emollients or emollient soap substitutes can be used instead [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Plewig and Jansen, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>].</li><li>Expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Borda, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Clark, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Okokon, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BMJ Best Practice, 2018</a>] is that stress may exacerbate seborrhoeic dermatitis.</li></ul><h5>Topical treatment</h5><ul><li>The recommendation to use anti-yeast creams such as ketoconazole, clotrimazole or miconazole is based on clinical guidance from the Primary Care Dermatology Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">PCDS, 2016</a>], the British Association of Dermatologists [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>], Rook’s Textbook of Dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>], a Cochrane review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Okokon, 2015</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Dessinioti, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Borda, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Harada, 2015</a>].<ul><li>Recommendations on reduction in frequency of application once symptoms are under control is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Dessinioti, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Borda, 2015</a>].</li><li>A systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Naldi, 2010</a>] assessing the efficacy of topical treatments for seborrhoeic dermatitis of the face and body in adults identified 3  randomized controlled trials  which compared ketoconazole 2% cream with placebo:<ul><li>The first RCT (n = 37) found that both ketoconazole and placebo improved erythema, scaling, papules, and pruritus, but the reduction in approximate mean symptom scores from baseline was greater in the ketoconazole group (19) than the placebo group (13) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Skinner et al, 1985</a>].</li><li>The second RCT (n = 20) found that, compared with placebo, ketoconazole 2% cream improved facial symptoms after 4 weeks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Green et al, 1987</a>]. Absolute risk for improving at least one symptom grade from baseline was 90% (9 of 10 people in the ketoconazole group compared with 0 of 10 people in the placebo group).</li><li>The third RCT (n = 459) found that, compared to placebo, ketoconazole 2% successfully treated significantly more people after 4 weeks 58/229 (25%) compared with 32/320 (14%) for placebo (p=0.0014) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Elewski et al, 2006</a>].</li></ul></li></ul></li><li>Topical corticosteroids — the recommendation to add a mildly potent topical corticosteroid on the face and trunk is based on expert opinion in clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">WHO, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">PCDS, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>] , Rook’s Textbook of Dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>].  <ul><li>CKS could find no evidence for the duration of treatment with mild topical corticosteroids, but have based the recommendation to use these preparations, short-term (one or two weeks) on the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BNF 76, 2018</a>] and expert opinion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>]. Continuous long-term use of topical steroids increases the risk of local and systemic adverse reactions.</li></ul></li><li>Antifungal shampoos<ul><li>The recommendation on use of ketoconazole 2% shampoo for adolescents and adults is based on expert opinion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>] and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">ABPI, 2015b</a>].</li></ul></li></ul><h5>Prevention of recurrence</h5><ul><li>CKS could find no good quality evidence on maintenance treatment for seborrhoeic dermatitis of the face and body.</li><li>The recommendation to use ketoconazole cream less frequently once symptoms are under control are based on expert opinion from review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Dessinioti, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Borda, 2015</a>] and extrapolation from advice issued by the British Association of Dermatologists on how to prevent recurrence of seborrhoeic dermatitis of the scalp [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>].<ul><li>The British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BNF 76, 2018</a>] states that for people aged over 12 years ketoconazole 2% shampoo can be applied every 1–2 weeks for prophylaxis of seborrhoeic dermatitis.</li></ul></li></ul><h5>Follow up</h5><ul><li>CKS could find no guidelines or evidence on the follow up of seborrhoeic dermatitis of the face and body — recommendations are pragmatic.</li></ul><h5>Referral</h5><ul><li>The recommendation to refer if there is diagnostic uncertainty or the person is not responding to topical treatment is supported by clinical guidance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">PCDS, 2016</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>].</li><li>Immunodeficiency (including HIV infection) should be considered where seborrhoeic dermatitis is widespread or severe [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">WHO, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>].</li></ul><!-- end field d41dcfb2-0e84-4e38-80b3-f6252bd43d57 --><!-- end item 81d2795a-4a8d-4f87-8878-04af4264a985 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}